Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial

Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC): A structured summary of a study protocol for a randomised controlled trial

Abstract Objectives The hypothesis of the proposed intervention is that Granulocyte-macrophage colony-stimulating factor (GM-CSF) has profound effects on antiviral immunity, and can provide the stimulus to restore immune homeostasis in the lung with acute lung injury post COVID-19, and can promote l...

Full description

Bibliographic Details
Main Authors: Cedric Bosteels, Bastiaan Maes, Karel Van Damme, Elisabeth De Leeuw, Jozefien Declercq, Anja Delporte, Bénédicte Demeyere, Stéfanie Vermeersch, Marnik Vuylsteke, Joren Willaert, Laura Bollé, Yuri Vanbiervliet, Jana Decuypere, Frederick Libeer, Stefaan Vandecasteele, Isabelle Peene, Bart Lambrecht
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Trials
Subjects:
COVID-19
Randomised controlled trial
protocol
sargramostim
GM-CSF
leukine®
Online Access:http://link.springer.com/article/10.1186/s13063-020-04451-7

Internet

http://link.springer.com/article/10.1186/s13063-020-04451-7

Similar Items